20 June 2013
Keywords: roche/aspreva, cellcept, enters, ln, trial, canada, aspreva
Article | 08 August 2005
Canada's Aspreva Pharmaceuticals has begun patient dosing in a pivotal Phase III clinical study evaluating CellCept (mycophenolate mofetil) for
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 August 2005
1 August 2005
19 June 2013
© 2013 thepharmaletter.com